Spontaneous Metastasis Model Method, 100% mLN Rate
Summary
US20260108632A1 is a published patent application disclosing a method for producing a spontaneous metastasis model using recombinant carcinoma cells engineered with luciferase-based expression systems. The disclosed models achieve approximately 100% metastasis incidence for mesenteric lymph node (mLN) invasion and 80–90% for secondary organs, providing statistically significant and robust kinetic data. The application was filed on October 18, 2022, under application number 18292945, with ten named inventors including Amit Sharma and colleagues.
“The models, according to various embodiments herein, achieve a higher metastasis incidence rate, in an instance about 100% for mesenteric lymph node (mLN) invasion and about 80 to 90% for secondary organs.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
US20260108632A1 discloses a new method for producing a spontaneous metastasis model involving the transplantation of recombinant carcinoma cells with increased invasiveness, decreased tumorigenic properties, and a luciferase gene expression system into orthotopic positions in an animal. The model reportedly achieves approximately 100% metastasis incidence for mesenteric lymph nodes and 80–90% for secondary organs, offering improved statistical significance over conventional models.
For pharmaceutical and biotechnology researchers, this patent application signals potential prior art considerations for any overlapping metastasis or cancer-model research programs. While not yet granted, the application establishes a priority date of October 18, 2022, which could affect freedom-to-operate analyses for companies developing related cancer therapeutics or diagnostic models.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD FOR PRODUCING A SPONTANEOUS METASTASIS MODEL
Application US20260108632A1 Kind: A1 Apr 23, 2026
Inventors
Amit SHARMA, Debabani Roy CHOWDHURY, Garima SHARMA, Samrat ROY, Manoj PANDRE, Soo-Woong LEE, ChangWook PARK, Rajesh KUMAR RK, Sundarajan KANNAN, Arnab Roy CHOWDHURY
Abstract
Method for producing a spontaneous metastasis model is disclosed herein. The models, according to various embodiments herein, achieve a higher metastasis incidence rate, in an instance about 100% for mesenteric lymph node (mLN) invasion and about 80 to 90% for secondary organs. The models are kinetic model having a luciferase-based expression system that provide more statistically significant and robust data. The embodiments herein further include a method for producing the model for metastasis, comprising transplanting recombinant carcinoma cells having increased invasiveness and decreased tumorigenic properties and luciferase gene expression system, in one or more orthotopic positions in an animal.
CPC Classifications
A61K 49/0008 A01K 67/0271 A61P 35/04 C12N 15/85 A01K 2207/12 A01K 2207/15 A01K 2227/105 A01K 2267/0331
Filing Date
2022-10-18
Application No.
18292945
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.